EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Implementation of amotosalen plus ultraviolet A ‐mediated pathogen reduction for all platelet concentrates in France : Impact on the risk of transfusion‐transmitted infections

Pascale Richard iD, Elodie Pouchol, Imad Sandid, Laurent Aoustin, Caroline Lefort, Anne-Gaële Chartois, Alexis Baima, Lucile Malard, Caroline Bacquet, Virginie Ferrera-Tourenc, Pierre Gallian iD, Syria Laperche iD und 3 weitere

Vox Sanguinis · 2024-03 · 119 (3) · 212-218

DOI: 10.1111/vox.13574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 28.12.2023. Verfasst von Pascale Richard und 14 weiteren Autor:innen. Beteiligte Einrichtung: Etablissement Français du Sang, La Plaine St-Denis, France. Hauptthemen laut MEDLINE: Furocoumarins, Transfusion Reaction. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Pathogen reduction (PR) technology may reduce the risk of transfusion‐transmitted infections (TTIs), notably transfusion‐transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand. The study aimed to assess the impact of PR PC on TTI and TTBI near‐miss occurrences. Materials and Methods TTI and TTBI near‐miss occurrences were compared before and after 100% PR implementation. The study period ran from 2013 to 2022. Over 300,000 PCs were transfused yearly.

Results

No PC‐related transmission of human immunodeficiency virus, hepatitis C virus, hepatitis B virus and human T‐cell lymphotropic virus was reported throughout the study period. PC‐mediated hepatitis E virus and hepatitis A virus infections occurred irrespective of PR implementation. Mean PC‐mediated TTBI occurrence before PR‐PC implementation was 3/year (SD: 1; n = 15; 1/92,687 PC between 2013 and 2016) with a fatal outcome in two patients. Since PR implementation, one TTBI has been reported (day 4 PC, Bacillus cereus ) (1/1,645,295 PC between 2018 and 2022; p < 0.001). Two PR PC quarantined because of a negative swirling test harboured bacteria: a day 6 PC in 2021 ( B. cereus and Staphylococcus epidermidis ) and a day 7 PC in 2022 ( Staphylococcus aureus ). Five similar occurrences with untreated PC were reported between 2013 and 2020.

Conclusion

Transfusion of 100% PR PC resulted in a steep reduction in TTBI occurrence. TTBI may, however, still occur. Pathogen‐reduced PC‐related TTI involving non‐enveloped viruses occurs as well.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FurocoumarinsTransfusion ReactionHumansBlood PlateletsBlood TransfusionBacteriaPlatelet TransfusionUltraviolet Rays

Stichwörter der Autor:innen

pathogen reductionplatelet concentratetransfusion-transmitted infection

Substanzen

amotosalenFurocoumarins

Autor:innen und Institutionen

  • Etablissement Français du Sang, La Plaine St-Denis, France.
  • Agence Nationale de Sécurité du Médicament (ANSM), St-Denis, France.
  • Etablissement Français du Sang, Nantes, France.
  • UMR RIGHT 1098, Inserm, Etablissement Français du Sang, Université de Franche-Comté, Besançon, France.

ORCID-Profile: Pascale Richard, Pierre Gallian, Syria Laperche, Pierre Tiberghien

Zitieren

APA

Richard, P., Pouchol, E., Sandid, I., Aoustin, L., Lefort, C., Chartois, A. G., Baima, A., Malard, L., Bacquet, C., Ferrera-Tourenc, V., Gallian, P., Laperche, S., Bliem, C., Morel, P., & Tiberghien, P. (2024). Implementation of amotosalen plus ultraviolet A ‐mediated pathogen reduction for all platelet concentrates in France : Impact on the risk of transfusion‐transmitted infections. Vox Sanguinis, 119(3), 212-218. https://doi.org/10.1111/vox.13574

Vancouver

Richard P, Pouchol E, Sandid I, Aoustin L, Lefort C, Chartois AG, et al. Implementation of amotosalen plus ultraviolet A ‐mediated pathogen reduction for all platelet concentrates in France : Impact on the risk of transfusion‐transmitted infections. Vox Sanguinis. 2024;119(3):212-218. doi:10.1111/vox.13574

BibTeX
@article{Richard2024,
  author = {Richard, Pascale and Pouchol, Elodie and Sandid, Imad and Aoustin, Laurent and Lefort, Caroline and Chartois, Anne-Gaële and Baima, Alexis and Malard, Lucile and Bacquet, Caroline and Ferrera-Tourenc, Virginie and Gallian, Pierre and Laperche, Syria and Bliem, Cathy and Morel, Pascal and Tiberghien, Pierre},
  title = {Implementation of amotosalen plus ultraviolet A ‐mediated pathogen reduction for all platelet concentrates in France : Impact on the risk of transfusion‐transmitted infections},
  journal = {Vox Sanguinis},
  year = {2024},
  volume = {119},
  number = {3},
  pages = {212--218},
  doi = {10.1111/vox.13574}
}
Kostenlos starten →